Anjali Owens

10.2k total citations · 2 hit papers
123 papers, 1.8k citations indexed

About

Anjali Owens is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Epidemiology. According to data from OpenAlex, Anjali Owens has authored 123 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Cardiology and Cardiovascular Medicine, 21 papers in Surgery and 14 papers in Epidemiology. Recurrent topics in Anjali Owens's work include Cardiomyopathy and Myosin Studies (72 papers), Cardiovascular Function and Risk Factors (43 papers) and Cardiovascular Effects of Exercise (22 papers). Anjali Owens is often cited by papers focused on Cardiomyopathy and Myosin Studies (72 papers), Cardiovascular Function and Risk Factors (43 papers) and Cardiovascular Effects of Exercise (22 papers). Anjali Owens collaborates with scholars based in United States, United Kingdom and Spain. Anjali Owens's co-authors include Amy J. Sehnert, Andrew Wang, Mariell Jessup, Milind Y. Desai, Srihari S. Naidu, Stephen B. Heitner, Daniel Jacoby, David Zhang, Francis E. Marchlinski and Marc J. Semigran and has published in prestigious journals such as Circulation, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Anjali Owens

104 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy

2022 183 citations Milind Y. Desai, Anjali Owens et al. profile →
Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy

2024 34 citations Florian Rader, Artur Oręziak et al. JACC Heart Failure profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anjali Owens United States	23	1.5k	244	241	209	155	123	1.8k
Dimitrios A. Vrachatis Greece	17	784 0.5×	266 1.1×	240 1.0×	236 1.1×	226 1.5×	100	1.3k
Charalampos Kossyvakis Greece	17	722 0.5×	98 0.4×	168 0.7×	314 1.5×	99 0.6×	55	1.2k
Wen-Lieng Lee Taiwan	19	612 0.4×	189 0.8×	315 1.3×	193 0.9×	157 1.0×	107	1.2k
Sameer Ather United States	20	1.3k 0.9×	115 0.5×	242 1.0×	352 1.7×	186 1.2×	42	1.7k
Michael Kyriakidis Greece	24	1.6k 1.0×	173 0.7×	198 0.8×	146 0.7×	318 2.1×	58	2.0k
Theo E. Meyer United States	21	1.6k 1.1×	169 0.7×	399 1.7×	121 0.6×	105 0.7×	58	1.9k
Koichiro Fujisue Japan	19	582 0.4×	91 0.4×	196 0.8×	234 1.1×	117 0.8×	60	1.1k
Andrew Maitland Canada	20	916 0.6×	125 0.5×	509 2.1×	135 0.6×	114 0.7×	42	1.4k
Rafał Dworakowski United Kingdom	18	686 0.5×	404 1.7×	297 1.2×	168 0.8×	241 1.6×	97	1.3k
Maurizio Porcu Italy	23	1.6k 1.1×	154 0.6×	282 1.2×	979 4.7×	132 0.9×	57	2.6k

Countries citing papers authored by Anjali Owens

Since Specialization

Citations

This map shows the geographic impact of Anjali Owens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anjali Owens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anjali Owens more than expected).

Fields of papers citing papers by Anjali Owens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anjali Owens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anjali Owens. The network helps show where Anjali Owens may publish in the future.

Co-authorship network of co-authors of Anjali Owens

This figure shows the co-authorship network connecting the top 25 collaborators of Anjali Owens. A scholar is included among the top collaborators of Anjali Owens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anjali Owens. Anjali Owens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barriales‐Villa, Roberto, Pablo García‐Pavía, Iacopo Olivotto, et al.. (2025). Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy. Journal of the American Heart Association. 14(6). e038758–e038758. 5 indexed citations

Desai, Milind Y., Niccolò Maurizi, Elena Biagini, et al.. (2025). Pathophysiology and Therapeutic Needs in Nonobstructive Hypertrophic Cardiomyopathy. JACC Heart Failure. 13(11). 102658–102658.

Masri, Ahmad, Sara Saberi, Martin S. Maron, et al.. (2025). Cardiopulmonary Exercise Testing for Characterization of Hypertrophic Cardiomyopathy: A Meta‐Analysis. Journal of the American Heart Association. 14(17). e039551–e039551.

Olivotto, Iacopo, Pablo García‐Pavía, Zhuang Tian, et al.. (2025). Integrated efficacy and safety analysis of mavacamten monotherapy in patients with obstructive hypertrophic cardiomyopathy. European Heart Journal. 46(Supplement_1). 1 indexed citations

Saberi, Sara, Timothy C. Wong, Antonis Pantazis, et al.. (2024). Atrial Fibrillation in Hypertrophic Cardiomyopathy. SHILAP Revista de lepidopterología. 3(9). 101210–101210. 9 indexed citations

Ricci, Fabrizio, Giulia Renda, Sabina Gallina, et al.. (2024). Managing drug–drug interactions with mavacamten: A focus on combined use of antiarrhythmic drugs and anticoagulants. Heart Rhythm. 22(2). 510–525. 1 indexed citations

García‐Pavía, Pablo, Artur Oręziak, Ahmad Masri, et al.. (2024). Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy. European Heart Journal. 45(47). 5071–5083. 38 indexed citations

Raper, Anna, Benita Weathers, Theodore G. Drivas, et al.. (2024). Protocol for a type 3 hybrid implementation cluster randomized clinical trial to evaluate the effect of patient and clinician nudges to advance the use of genomic medicine across a diverse health system. Implementation Science. 19(1). 61–61. 3 indexed citations

Asatryan, Babken, Brittney Murray, Rafik Tadros, et al.. (2024). Promise and Peril of a Genotype‐First Approach to Mendelian Cardiovascular Disease. Journal of the American Heart Association. 13(21). e033557–e033557. 4 indexed citations

10.

Patel, Nirav, Naman S. Shetty, Akhil Pampana, et al.. (2024). Sex-Associated Differences in Clinical Outcomes After Septal Reduction Therapies in Hypertrophic Cardiomyopathy. Mayo Clinic Proceedings. 99(12). 1933–1944.

11.

Rodríguez‐Martínez, Marta, Kai Fenzl, Daniel Schraivogel, et al.. (2023). Mislocalization of pathogenic RBM20 variants in dilated cardiomyopathy is caused by loss-of-interaction with Transportin-3. Nature Communications. 14(1). 4312–4312. 18 indexed citations

12.

Wang, Andrew, John A. Spertus, Daniel Wojdyla, et al.. (2023). Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension. JACC Heart Failure. 12(3). 567–579. 7 indexed citations

13.

Cresci, Sharon, Richard G. Bach, Sara Saberi, et al.. (2023). Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM. Circulation. 149(7). 498–509. 11 indexed citations

14.

Wheeler, Matthew T., Iacopo Olivotto, Perry Elliott, et al.. (2023). Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption. JAMA Cardiology. 8(3). 240–240. 31 indexed citations

15.

Cremer, Paul, Jeffrey B. Geske, Anjali Owens, et al.. (2022). Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study. Circulation Cardiovascular Imaging. 15(12). e014986–e014986. 41 indexed citations

16.

Shah, Ravi A., Babken Asatryan, Ghaith Sharaf Dabbagh, et al.. (2022). Frequency, Penetrance, and Variable Expressivity of Dilated Cardiomyopathy–Associated Putative Pathogenic Gene Variants in UK Biobank Participants. Circulation. 146(2). 110–124. 45 indexed citations

17.

Asatryan, Babken, Angeliki Asimaki, Andrew P. Landstrom, et al.. (2021). Inflammation and Immune Response in Arrhythmogenic Cardiomyopathy: State-of-the-Art Review. Circulation. 144(20). 1646–1655. 58 indexed citations

18.

Jessup, Mariell, et al.. (2019). Clinical utility of surveillance and clinically prompted right heart catheterization in patients listed for heart transplantation. Catheterization and Cardiovascular Interventions. 95(1). 28–34. 1 indexed citations

19.

Park, Joseph, Michael G. Levin, Christopher M. Haggerty, et al.. (2019). A genome-first approach to aggregating rare genetic variants in LMNA for association with electronic health record phenotypes. Genetics in Medicine. 22(1). 102–111. 37 indexed citations

20.

Brisco, Meredith A., Steven G. Coca, Anjali Owens, et al.. (2013). Blood Urea Nitrogen/Creatinine Ratio Identifies a High-Risk but Potentially Reversible Form of Renal Dysfunction in Patients With Decompensated Heart Failure. Circulation Heart Failure. 6(2). 233–239. 107 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact